Cidara Therapeutics Submits NDA for Rezafungin

Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation Melinta...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news